Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | PCTP | Q9UKL6 | 8/20 | 0.49 |
| ▸ | STARD10 | Q9Y365 | 3/20 | 0.47 |
| ▸ | STARD7 | Q9NQZ5 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377302 | 0.93 | HTR6 (0.57) | DRD2DRD3HTR6PCTPSTARD10 | |
| SCHEMBL19377387 | 0.88 | GHSR (0.45) | DRD2DRD3HTR6PCTPSTARD10 | |
| SCHEMBL19377411 | 0.87 | PCTP (0.47) | DRD2DRD3HTR6PCTPSTARD10 | |
| SCHEMBL19377147 | 0.81 | POLB (0.52) | PCTPGHSRMEN1POLBKMT2A | |
| SCHEMBL19377401 | 0.80 | GHSR (0.70) | PCTPGHSR | |
| SCHEMBL19377430 | 0.77 | GHSR (0.46) | PCTPSTARD10STARD7GHSRMEN1 | |
| SCHEMBL19377260 | 0.74 | PCTP (0.46) | PCTPSTARD10STARD7GHSRMEN1 | |
| SCHEMBL19377297 | 0.72 | GHSR (0.47) | GHSRMEN1POLBKMT2AALDH1A1 | |
| SCHEMBL19377005 | 0.71 | GHSR (0.53) | PCTPSTARD10STARD7GHSR | |
| SCHEMBL19384137 | 0.70 | MLNR (0.39) | DRD2DRD3HTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | DRD2 4443/4885DRD3 4367/4885HTR6 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.